# FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

> **NCT04625907** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Birmingham** · enrollment: 1672 (estimated)

## Conditions studied

- Rhabdomyosarcoma

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Actinomycin D
- **DRUG:** Doxorubicin
- **DRUG:** Ifosfamide
- **DRUG:** Vincristine
- **DRUG:** Vinorelbine
- **DRUG:** Cyclophosphamide
- **DRUG:** Temozolomide
- **RADIATION:** radiotherapy
- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT04625907
- **Lead sponsor:** University of Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-17
- **Primary completion:** 2030-06
- **Final completion:** 2030-06
- **Target enrollment:** 1672 (ESTIMATED)
- **Last updated:** 2024-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04625907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04625907, "FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04625907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*